In our previous meta-analysis on the impact of mTOR-Is on overall infections after renal transplantation, we could already show that the lowest risk for CMV infections was present under a combination therapy of mTOR-I and CNI [8]. The gene discussed is MTOR; the disease is cytomegalovirus infection.